22:46 , Mar 22, 2018 |  BC Extra  |  Company News

An omnibus win for Omeros

A provision in the proposed omnibus appropriations bill approved Thursday by the House of Representatives may offer Omeros Corp. (NASDAQ:OMER) a lifeline for its struggling cataract surgery drug Omidria phenylephrine/ketorolac, sending the company's stock up...
23:42 , Nov 30, 2017 |  BC Week In Review  |  Company News

Omeros, Par settle Omidria patent infringement lawsuit

In October, Omeros Corp. (NASDAQ:OMER) said it and Par Pharmaceuticals Inc. settled a patent infringement lawsuit concerning Par's proposed generic version of Omeros' Omidria ketorolac/phenylephrine. Par, which Endo International plc (NASDAQ:ENDP) acquired in 2015, had...
23:02 , Nov 10, 2017 |  BC Extra  |  Company News

Omeros soars on single Phase III plan for OMS721

Omeros Corp. (NASDAQ:OMER) soared $4.08 (29%) to $18.17 Friday after announcing late Thursday that FDA will accept a single Phase III trial with a primary endpoint of proteinuria reduction to support approval of OMS721 to...
19:51 , Aug 18, 2017 |  BC Week In Review  |  Financial News

Omeros raises $68.3M in follow-on

On Aug. 15, Omeros Corp. (NASDAQ:OMER) raised $68.3 million through the sale of 3 million shares at $22.75 in a follow-on underwritten by Cantor Fitzgerald, H.C. Wainwright, JonesTrading Institutional Services and Maxim Group. Omeros' OMS721...
21:03 , Aug 15, 2017 |  BC Extra  |  Financial News

Omeros, Oxford Immunotec fall after pricing follow-ons

Shares of Omeros Corp. (NASDAQ:OMER) and Oxford Immunotec Global plc (NASDAQ:OXFD) both slipped on Tuesday after the companies priced follow-ons, raising over $108 million total. Omeros raised $68.3 million through the sale of 3 million...
07:00 , Aug 11, 2016 |  BC Extra  |  Financial News

Amarin, Omeros fall after follow-ons

Shares of Amarin Corp. plc (NASDAQ:AMRN) and Omeros Corp. (NASDAQ:OMER) both slipped on Thursday after the companies priced follow-ons. Amarin raised $60.1 million through the sale of 21.1 million ADSs at $2.85. Each ADS represents...
02:27 , Mar 9, 2016 |  BC Extra  |  Company News

Omeros rises after laying out aHUS therapy plans

Omeros Corp. (NASDAQ:OMER) gained $2.08 (16%) to $15.07 on Tuesday after providing an update on its Phase III and regulatory submission plans for OMS721 to treat atypical hemolytic uremic syndrome (aHUS) following a meeting with...
08:00 , Nov 2, 2015 |  BC Week In Review  |  Company News

Omeros sales and marketing update

Omeros launched OMIDRIAssure, an expanded access program to provide reimbursement assistance for cataract surgery patients on Omidria . Omidria is free during surgery for financially eligible uninsured and government-insured patients under the “Equal Access” program....
07:00 , Jun 8, 2015 |  BC Week In Review  |  Clinical News

Omidria regulatory update

EMA’s CHMP recommended approval of Omidria phenylephrine/ketorolac to maintain intraoperative mydriasis (pupil size), prevent intraoperative miosis and reduce postoperative ocular pain in patients undergoing intraocular lens replacement surgery. The combination of the anti-inflammatory agent ketorolac...
07:00 , Apr 13, 2015 |  BC Week In Review  |  Company News

Omeros sales and marketing update

Omeros launched Omidria in the U.S. to maintain intraoperative mydriasis (pupil size) by preventing intraoperative miosis and to reduce postoperative ocular pain in patients undergoing cataract surgery or intraocular lens replacement surgery. The wholesale acquisition...